UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE PATENT TRIAL AND APPEAL BOARD
BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. Petitioner
V.
GENENTECH, INC. Patent Owner
U.S. Patent No.6.407.213

EXPERT DECLARATION OF GEOFFREY HALE, PH.D. IN SUPPORT OF PETITION FOR *INTER PARTES* REVIEW OF PATENT NO.6,407,213

Case IPR2017-02031



TABLE OF CONTENTS

			Page
I.	QUA	ALIFICATIONS AND BACKGROUND	1
	À.	Education and Experience	
	В.	Bases for Opinions and Materials Considered	
	C.	Scope of Work	
II.	LEG	AL STANDARDS	
III.		SON OF ORDINARY SKILL IN THE ART	
IV.		MARY OF OPINIONS	
\mathbf{V} .		2213 PATENT [EX. 1001]	
VI.		CKGROUND	
· _•	A.	Antibody Structure and Function	
	В.	Monoclonal Antibodies Expanded Therapeutic and Diagnostic U	
	2,	of Antibodies	
	C.	Immunogenic Reaction in Humans With Monoclonal Antibody	
		Therapy	37
	D.	Molecular Characterization of Antibody Structure and Function.	
	E.	Antigen Binding Regions	
	F.	Framework Region Important for Antigen Binding	
	G.	Chimeric Antibodies	
	H.	Antibody Humanization	
VII.	SCO	PE AND CONTENT OF THE PRIOR ART REFERENCES	
	A.	EP 0403156 "Improved Monoclonal Antibodies Against the Hun	man
		Alpha/Beta T-Cell Receptor, Their Production and Use" Publish	
		December 19, 1990 ("Kurrle") [Ex. 1071]	
	В.	Queen et al. "A Humanized Antibody that Binds to the Interleuk	
		Receptor" PNAS 86:10029-33 (1989) ("Queen 1989") [Ex. 1034]	171
	C.	PCT Publication No.WO 90/07861 ("Queen 1990") [Ex. 1050]	75
	D.	U.S. Patent No. 5,530,101 ("the '101 patent") [Ex. 1136]	79
	E.	Jones et al., "Replacing the Complementarity-Determining Regi	ons in
		a Human Antibody with those from a Mouse," Nature 321:522-2	25
		(1986) ("Jones")	81
	F.	Protein Data Bank Database	83
	G.	Tramontano et al. "Framework Residue 71 is a Major Determina	ant of
		the Position and Conformation of the Second Hypervariable Reg	gion in
		the VH Domains of Immunoglobulins" J. Mol. Biol. 215:175-8	32
		(1990) ("Tramontano") [Ex. 1051]	86



	Н.	Kabat	t et al. "Sequences of Proteins of Immunological Interest", 4 th	
		Ed., p	pp. iii, 41-49, 167-76 (1987) ("Kabat 1987") [Ex. 1052]	.87
	I.	Choth	nia and Lesk. "Canonical Structures for the Hypervariable	
		Regio	ons of Immunoglobulins" <i>J. Mol. Biol.</i> 196:901-17 (1987)	
		("Cho	othia & Lesk'') [Ex. 1062]	.88
	J.	Riech	mann et al, "Reshaping Human Antibodies For Therapy,"	
		Natur	re, 332:323-27 (1988) ("Riechmann") [Ex. 1069]	.88
VIII.	UNPA		TABILITY OF THE '213 PATENT	
	A.	Claim	ns 1, 2, 4, 25, 29, 62, 63, 66, 69, 71, 75, 76, 78, 80 and 81 of the	e
		'213 1	Patent are Anticipated by Kurrle [Ex. 1071]	.89
		1.	Claim 1 of the '213 patent is anticipated by Kurrle	.89
		2.	Dependent claims 2, 25 and 29 are anticipated by Kurrle	91
		3.	Independent claim 63 is anticipated by Kurrle	.93
		4.	Independent claim 66 and dependent claims 71, 72, 75 and 76	ó,
			and 78 are anticipated by Kurrle	.94
		5.	Claims 4, 62, and 69 are anticipated by Kurrle	.95
		6.	Independent claim 80 and dependent claim 81 are anticipated	
			by Kurrle	.97
	B.		ns 1, 2, 4, 29, 62, 63, 64, 80 and 81 of the '213 Patent are	
		Antic	ipated by Queen 1990	.99
		1.	Independent Claim 1 of the '213 Patent is anticipated by Que	
			1990 [Ex. 1050]	
		2.	Dependent Claim 2 of the '213 Patent is anticipated by Queer	1
			1990	
		3.	Dependent Claim 4 of the '213 Patent is anticipated by Queer	
			1990	
		4.	Dependent Claim 29 of the '213 Patent is anticipated by Quee	
			19901	07
		5.	Independent Claim 62 of the '213 Patent is anticipated by	
			Queen 1990	08
		6.	Independent Claim 63 of the '213 Patent is anticipated by	
		_	Queen 1990	09
		7.	Independent Claim 64 of the '213 Patent is anticipated by	4.0
		•	Queen 1990	10
		8.	Independent Claim 80 of the '213 Patent is anticipated by	4
		0	Queen 1990	12
		9.	Dependent Claim 81 of the '213 Patent is anticipated by Quee	
			1990	14



C.	Clan	ms 1, 2, 4, 25, 29, 62-64, 66-67, 69, 71-73, 75-78, and 80-81 of				
	the '	213 Patent are obvious over Queen 1990 in view of Kurrle, and				
	Chot	thia & Lesk115				
	1.	Claim 1 is obvious over Queen 1990 and Kurrle117				
	2.	Claims 2, 25 and 29 are obvious over Queen 1990 and Kurrle				
	3.	Claim 4 is obvious over Queen 1990 and Kurrle123				
	4.	Claim 62 is obvious over Queen 1990 in view of Kurrle123				
	5.	Claim 63 is obvious over Queen 1990 in view of Kurrle124				
	6.	Claim 64 is obvious over Queen 1990 in view of Kurrle126				
	7.	Claim 66 is obvious over Queen 1990 in view of Kurrle128				
	8.	Claims 67, 71, 72, 75, 76 and 78 are obvious over Queen 1990				
		in view of Kurrle				
	9.	Claim 69 is obvious over Queen 1990 in view of Kurrle131				
	10.	Claims 73 and 77 are obvious in view of Queen 1990, Kurrle				
		and Chothia & Lesk				
	11.	Claims 80 and 81 are obvious over Queen 1990 in view of				
		Kurrle				
D.		Claims 1, 2, 4, 25, 29, 62, 63, 64, 66, 69, 71, 73, 75-78, 80 and 81 are				
		cipated by Jones [Ex. 1033]				
	1.	Independent Claim 1 of the '213 Patent is anticipated by Jones				
		[Ex. 1033]				
	2.	Claims 2, 25, and 29 of the '213 Patent is anticipated by Jones				
	2	[Ex. 1033]				
	3.	Independent Claim 66 and Dependent Claims 71, 73, and 75-78				
	4	are Anticipated by Jones				
	4. 5.	Claims 4, 62, 64, and 69 are anticipated by Jones				
	5.	Independent Claim 80 and Dependent Claim 81 Are Anticipated by Jones				
E.	Clair	m 63 is anticipated by Jones, or obvious in view of Jones [Ex.				
Ľ.		B] and Riechmann [Ex. 1069]145				
F.		ms 1, 2, 4, 25, 29, 62—64, 66-67, 69 and 71-73, 75-78, and 80-81				
г.		of the '213 Patent are obvious in view of Queen 1989 or Queen 1990				
		the PDB database				
	1.	Independent Claim 1 of the '213 Patent is obvious in view of				
	1.	Queen 1989 and the PDB database				
	2.	Independent Claim 1 of the '213 Patent is obvious in view of				
	4.	Queen 1990 and the PDB database				



3.	Dependent Claims 2, 25 and 29 of the '213 Patent are obvious in view of Queen 1989 or Queen 1990 and the PDB database
4.	Dependent claim 4 of the '213 Patent is obvious in view of
т.	Queen 1990 and the PDB database
5.	Independent Claim 62 of the '213 Patent is obvious in view of
	Queen 1990 and the PDB database 164
6.	Independent Claim 63 of the '213 Patent is obvious in view of
	Queen 1989 or Queen 1990 and the PDB database165
7.	Independent Claim 64 of the '213 Patent is obvious in view of
	Queen 1990 and the PDB database
8.	Independent Claim 66 of the '213 Patent is obvious in view of
	Queen 1989 or Queen 1990 and the PDB database
9.	Dependent Claims 67, 71-73 and 78 of the '213 Patent are
	obvious in view of Queen 1989 or Queen 1990 and the PDB
4.0	database
10.	Dependent Claim 72 of the '213 patent is obvious in view of
11	Queen 1989 or Queen 1990, and the PDB database171
11.	Dependent Claim 75 of the '213 patent is obvious in view of
12.	Queen 1989 or Queen 1990 and the PDB database
14.	Dependent Claim 75 of the '213 patent is obvious in view of Queen 1989 or Queen 1990 and the PDB database, and further
	in view of Tramontano
13.	Dependent Claims 76-77 of the '213 Patent are obvious in view
10.	of Queen 1989 or Queen 1990 and the PDB database, and
	optionally in view of Tramontano
14.	Dependent Claim 69 of the '213 Patent is obvious in view of
	Queen 1990 and the PDB database
15.	Independent Claim 80 of the '213 Patent is obvious in view of
	Queen 1989 or Queen 1990 and the PDB database183
16.	Dependent Claim 81 of the '213 Patent is obvious in view of
	Queen 1989 or Queen 1990 and the PDB database
	ms 4, 62, 64 and 69 of the '213 Patent are obvious in view of
Que	en 1989, the PDB database and in view of Kabat 1987186
1.	Independent Claim 62 of the '213 Patent is obvious in view of
	Queen 1989, the PDB database and in view of Kabat 1987186
2.	Dependent Claims 4 and 69 of the '213 Patent are obvious in
	view of Queen 1989 and the PDB database, and in view of
	Kabat 1987 189



G.

DOCKET A L A R M

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

